Biomea Fusion Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended March 31, 2026OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period fromtoCommission File Number: 001-40335 Biomea Fusion, Inc. (Exact Name of Registrant as Specified in its Charter) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) hasbeen subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒Emerging growth company☒ Accelerated filer☐ Smaller reporting company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of May 7, 2026, the registrant had 72,299,440 shares of common stock, $0.0001 par value per share, outstanding. Table of Contents PART I.FINANCIAL INFORMATIONItem 1.Financial Statements (Unaudited)1Condensed Balance Sheets1Condensed Statements of Operations and Comprehensive Loss2Condensed Statements of Stockholders’ Equity3Condensed Statements of Cash Flows4Notes to Unaudited Condensed Financial Statements5Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations13Item 3.Quantitative and Qualitative Disclosures About Market Risk21Item 4.Controls and Procedures21PART II.OTHER INFORMATIONItem 1.Legal Proceedings22Item 1A.Risk Factors22Item 2.Unregistered Sales of Equity Securities and Use of Proceeds73Item 3.Defaults Upon Senior Securities73Item 4.Mine Safety Disclosures73Item 5.Other Information73Item 6.Exhibits74Signatures75 Special Note Regarding Forward Looking Statements This Quarterly Report on Form 10-Q contains forward-looking statements about us and our industry that involve substantial risksand uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q,including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans,objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,”“due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,”“target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or thenegative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to,statements about: •our financial performance;•the sufficiency of our existing cash, cash equivalents and restricted cash to fund our future operating expenses and capitalexpenditure requirements;•our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;•our anticipated use of our existing cash, cash equivalents and restricted cash;•the implementation of our strategic plans for our business and product candidates;•the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials andinvestigational new drug (IND) applications and other regulatory submissions;•our ability to develop our product candidates for the treatment of type 1 and type 2 diabetes, obesity and other metabolicdiseases;•the timing, progress and focus of our ongoing and future clinical trials, and the reporting of data from those trials;•the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other favorable results;•our plans relating to the clinical development of our product candidates, including the disease areas to be evaluated;•our a